Ravijuhendid
Taba P., Asser T., Krikmann Ü., Paju T., Olt E., Kanarik E.,
Ankru K., Kivil H., Taurafeldt E., Aasa M. Parkinsoni tõve
Eesti ravijuhend Parkinsoni tõve Eesti ravijuhend: 102, 2008
Linnamägi Ü., Vahter L., Jaanson K., Tomberg T., Lüüs SM.,
Gross-Paju K., Kreis A., Toomsoo T. Dementsuse Eesti ravi-,
tegevus- ja diagnostikajuhend Dementsuse Eesti ravi-,
tegevus- ja diagnostikajuhend: 43, 2007
Patsiendijuhend:
Parkinsoni tõbi
Rahvusvahelised publikatsioonid:
Liu G, Ni C, Zhan J, Li W, …Taba P, et al. Mitochondrial
haplogroups and cognitive progression in Parkinson's
disease. Brain. 2023;146(1):42-9.
Sugier PE, Lucotte EA, Domenighetti C,
…Taba P, et al. Investigation of Shared Genetic Risk Factors
Between Parkinson's Disease and Cancers. Mov Disord.
2023;38(4):604-15.
Boutet A, Loh A, Germann J, Machnowska
M, Scantlebury N, Vetkas A, et al. A Cautionary Tale of
Magnetic Resonance-Guided Focused Ultrasound
Thalamotomy-Induced White Matter Lesions. Mov Disord.
2022;37(9):1953-5.
Brunklaus A, Brünger T, Feng T, ..Vaher
U, et al. The gain of function SCN1A disorder spectrum:
novel epilepsy phenotypes and therapeutic implications.
Brain. 2022;145(11):3816-31.
Deuschl G, Antonini A, Costa J,
Śmiłowska K, Berg D, Corvol JC, et al. European Academy of
Neurology/Movement Disorder Society - European Section
guideline on the treatment of Parkinson's disease: I.
Invasive therapies. Eur J Neurol. 2022;29(9):2580-95.
Deuschl G, Antonini A, Costa J, …Taba
P, et al. European Academy of Neurology/Movement Disorder
Society-European Section Guideline on the Treatment of
Parkinson's Disease: I. Invasive Therapies. Mov Disord.
2022;37(7):1360-74.
Domenighetti C, Douillard V, …Taba P,
et al. The Interaction between HLA-DRB1 and Smoking in
Parkinson's Disease Revisited. Mov Disord.
2022;37(9):1929-37.
Domenighetti C, Sugier PE, ..Taba P, et
al. Dairy Intake and Parkinson's Disease: A Mendelian
Randomization Study. Mov Disord. 2022;37(4):857-64.
Domenighetti C, Sugier PE, Sreelatha
AAK, …Taba P, et al. Mendelian Randomisation Study of
Smoking, Alcohol, and Coffee Drinking in Relation to
Parkinson's Disease. J Parkinsons Dis. 2022;12(1):267-82.
Grover S, Kumar Sreelatha AA, Pihlstrom
L, …Taba P, et al. Genome-wide Association and Meta-analysis
of Age at Onset in Parkinson Disease: Evidence From the
COURAGE-PD Consortium. Neurology. 2022;99(7):e698-e710.
Loh A, Gwun D, Chow CT, Boutet A,
Tasserie J, Germann J, et al. Probing responses to deep
brain stimulation with functional magnetic resonance
imaging. Brain Stimul. 2022;15(3):683-94.
Medijainen K, Pääsuke M, Lukmann A,
Taba P. Structured guideline-based physiotherapy reduces
difficulties in activities of daily living in Parkinson's
disease. NeuroRehabilitation. 2022;50(1):47-56.
Branovets J, Karro N, Barsunova K,
Laasmaa M, Lygate CA, Vendelin M, et al. Cardiac expression
and location of hexokinase changes in a mouse model of pure
creatine deficiency. Am J Physiol Heart Circ Physiol.
2021;320(2):H613-h29.
Gatsios D, Antonini A, Gentile G, …Taba
P, et al. Education on palliative care for Parkinson
patients: development of the "Best care for people with
late-stage Parkinson's disease" curriculum toolkit. BMC Med
Educ. 2021;21(1):538.
Innos J, Hickey MA. Using Rotenone to
Model Parkinson's Disease in Mice: A Review of the Role of
Pharmacokinetics. Chem Res Toxicol. 2021;34(5):1223-39.
Kurvits L, Lättekivi F, Reimann E,
Kadastik-Eerme L, Kasterpalu KM, Kõks S, et al.
Transcriptomic profiles in Parkinson's disease. Exp Biol Med
(Maywood). 2021;246(5):584-95.
Kwong AK, Tsang MH, Fung JL, Mak CC,
Chan KL, Rodenburg RJT, et al. Exome sequencing in
paediatric patients with movement disorders. Orphanet J Rare
Dis. 2021;16(1):32.
Liu G, Peng J, Liao Z, Locascio JJ,
…Taba P, et al. Genome-wide survival study identifies a
novel synaptic locus and polygenic score for cognitive
progression in Parkinson's disease. Nat Genet.
2021;53(6):787-93.
Mencacci NE, Brockmann MM, Dai J,
Pajusalu S, Atasu B, Campos J, et al. Biallelic variants in
TSPOAP1, encoding the active-zone protein RIMBP1, cause
autosomal recessive dystonia. J Clin Invest. 2021;131(7).
Muldmaa M, Mencacci NE, Pittman A,
Kadastik-Eerme L, Sikk K, Taba P, et al. Community-based
genetic study of Parkinson's disease in Estonia. Acta Neurol
Scand. 2021;143(1):89-95.
Nurm K, Sepp M, Castany-Pladevall C,
Creus-Muncunill J, Tuvikene J, Sirp A, et al.
Isoform-Specific Reduction of the Basic Helix-Loop-Helix
Transcription Factor TCF4 Levels in Huntington's Disease.
eNeuro. 2021;8(5).
Renko JM, Mahato AK, Visnapuu T,
Valkonen K, Karelson M, Voutilainen MH, et al.
Neuroprotective Potential of a Small Molecule RET Agonist in
Cultured Dopamine Neurons and Hemiparkinsonian Rats. J
Parkinsons Dis. 2021;11(3):1023-46.
Sarica C, Fomenko A, Iorio-Morin C,
Zemmar A, Yamamoto K, Vetkas A, et al. Letter to the Editor.
Clinical Rating Scale for Tremor: a needed clarification. J
Neurosurg. 2021;136(3):932-3.
Beck DB, Petracovici A, He C, Moore HW,
Louie RJ, Ansar M, et al. Delineation of a Human Mendelian
Disorder of the DNA Demethylation Machinery: TET3
Deficiency. Am J Hum Genet. 2020;106(2):234-45.
Ennok M, Sikk K, Haldre S, Taba P.
Cognitive profile of patients with manganese-methcathinone
encephalopathy. Neurotoxicology. 2020;76:138-43.
Mahato AK, Kopra J, Renko JM, Visnapuu
T, Korhonen I, Pulkkinen N, et al. Glial cell line-derived
neurotrophic factor receptor Rearranged during transfection
agonist supports dopamine neurons in Vitro and enhances
dopamine release In Vivo. Mov Disord. 2020;35(2):245-55.
Tamás G, Fabbri M, Falup-Pecurariu C,
Teodoro T, … Kadastik-Eerme L, et al. Lack of Accredited
Clinical Training in Movement Disorders in Europe, Egypt,
and Tunisia. J Parkinsons Dis. 2020;10(4):1833-43.
Whiffin N, Armean IM, Kleinman A, …Esko
T, et al. The effect of LRRK2 loss-of-function variants in
humans. Nat Med. 2020;26(6):869-77.
Billingsley KJ, Lättekivi F, Planken A,
Reimann E, Kurvits L, Kadastik-Eerme L, et al. Analysis of
repetitive element expression in the blood and skin of
patients with Parkinson's disease identifies differential
expression of satellite elements. Sci Rep. 2019;9(1):4369.
Kadastik-Eerme L, Taba N, Asser T, Taba
P. Incidence and Mortality of Parkinson's Disease in
Estonia. Neuroepidemiology. 2019;53(1-2):63-72.
Kolk A, Saard M, Pertens L, Kallakas T,
Sepp K, Kornet K. Structured Model of Neurorehab: A Pilot
Study of Modern Multitouch Technology and Virtual Reality
Platforms for Training Sociocognitive Deficit in Children
with Acquired Brain Injury. Appl Neuropsychol Child.
2019;8(4):326-32.
Lubi K. The adaptation of everyday
practices in the adoption of chronic illness. Health
(London). 2019;23(3):325-43.
Medijainen K, Pääsuke M, Lukmann A,
Taba P. Versatile guideline-based physiotherapy intervention
in groups to improve gait speed in Parkinson's disease
patients. NeuroRehabilitation. 2019;44(4):579-86.
Randver R, Davel K, Toomsoo T.
High-frequency repetitive transcranial magnetic stimulation
to the left dorsolateral prefrontal cortex of patients with
Parkinson's disease and treatment-resistant depression: a
pilot study. Neurocase. 2019;25(3-4):80-90.
Rätsep T, Asser T. Influence of
alarming auditory cues on viscoelastic stiffness of skeletal
muscles in patients with Parkinson's disease. Clin Biomech
(Bristol, Avon). 2019;62:93-5.
Toomsoo T, Liepelt-Scarfone I, Berg D,
Kerner R, Pool AH, Kadastik-Eerme L, et al. Effect of Age on
Substantia Nigra Hyper-echogenicity in Parkinson's Disease
Patients and Healthy Controls. Ultrasound Med Biol.
2019;45(1):122-8.
Yakoreva M, Kahre T, Žordania R,
Reinson K, Teek R, Tillmann V, et al. A retrospective
analysis of the prevalence of imprinting disorders in
Estonia from 1998 to 2016. Eur J Hum Genet.
2019;27(11):1649-58.
Randver R. Repetitive transcranial
magnetic stimulation of the dorsolateral prefrontal cortex
to alleviate depression and cognitive impairment associated
with Parkinson's disease: A review and clinical
implications. J Neurol Sci. 2018;393:88-99.
Altpere A, Raud S, Sütt S, Reimets R, Visnapuu T, Toots M, Vasar E. Mild stress induces brain region-specific alterations of selective ER stress markers' mRNA expression in Wfs1-deficient mice. Behav Brain Res. 2018 Oct 15;352:94-98
Kadastik-Eerme L, Taba N, Asser T, Taba P. The increasing prevalence of Parkinson's disease in Estonia. Acta Neurol Scand. 2018 Sep;138(3):251-258
Römhild J, Fleischer S, Meyer G, Stephan A, Zwakhalen S, Leino-Kilpi H, Zabalegui A, Saks K, Soto-Martin M, Sutcliffe C, Rahm Hallberg I, Berg A; RightTimePlaceCare Consortium.. Inter-rater agreement of the Quality of Life-Alzheimer's Disease (QoL-AD) self-rating and proxy rating scale: secondary analysis of RightTimePlaceCare data. Health Qual Life Outcomes. 2018 Jun 28;16(1):131
Tiigimäe-Saar J, Tamme T, Rosenthal M, Kadastik-Eerme L, Taba P. Saliva changes in Parkinson's disease patients after injection of Botulinum neurotoxin type A. Neurol Sci. 2018 May;39(5):871-877
Ivask M, Pajusalu S, Reimann E, Kõks S. Hippocampus and Hypothalamus RNA-sequencing of WFS1-deficient Mice. Neuroscience. 2018 Mar 15;374:91-103.
Bradburn S, McPhee J, Bagley L, Carroll M, Slevin M, Al-Shanti N, Barnouin Y, Hogrel JY, Pääsuke M, Gapeyeva H, Maier A, Sipilä S, Narici M, Robinson A, Mann D, Payton A, Pendleton N, Butler-Browne G, Murgatroyd C. Dysregulation of C-X-C motif ligand 10 during aging and association with cognitive performance. Neurobiol Aging. 2018 Mar;63:54-64
Smirnova J, Kabin E, Järving I, Bragina O, Tõugu V, Plitz T, Palumaa P. Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. a-Lipoic acid as a potential anti-copper agent. Sci Rep. 2018 Jan 23;8(1):1463
Yau Y, Zeighami Y, Baker TE, Larcher K, Vainik U, Dadar M, Fonov VS, Hagmann P, Griffa A, Mišic B, Collins DL, Dagher A. Network connectivity determines cortical thinning in early Parkinson's disease progression. Nat Commun. 2018 Jan 2;9(1):12
Porosk R, Terasmaa A, Mahlapuu R, Soomets U, Kilk K. Metabolomics of the Wolfram Syndrome 1 Gene (Wfs1) Deficient Mice. OMICS. 2017 Dec;21(12):721-732
Mann AP, Scodeller P, Hussain S, Braun GB, Mölder T, Toome K, Ambasudhan R, Teesalu T, Lipton SA, Ruoslahti E. Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. Nat Commun. 2017 Nov 10;8(1):1403. doi: 10.1038/s41467-017-01096-0. Erratum in: Nat Commun. 2018 Mar 9;9(1):10705.
Porosk R, Kilk K, Mahlapuu R, Terasmaa A, Soomets U. Glutathione system in Wolfram syndrome 1-deficient mice. Mol Med Rep. 2017 Nov;16(5):7092-7097
Toomsoo T, Randver R, Liepelt-Scarfone I, Kadastik-Eerme L, Asser T, Rubanovits I, Berg D, Taba P. Prevalence of depressive symptoms and their association with brainstem raphe echogenicity in patients with Parkinson's disease and non-PD controls. Psychiatry Res Neuroimaging. 2017 Oct 30;268:45-49
Kadastik-Eerme L, Taba N, Asser T, Taba P. Factors associated with motor complications in Parkinson's disease. Brain Behav. 2017 Sep 25;7(10):e00837
Georgiopoulos G, Chrysohoou C, Errigo A, Pes G, Metaxa V, Zaromytidou M, Skoumas J, Kariori M, Lazaros G, Vogiatzi G, Poulain M, Tousoulis D, Pitsavos C, Stefanadis C. Arterial aging mediates the effect of TNF-a and ACE polymorphisms on mental health in elderly individuals: insights from IKARIA study. QJM. 2017 Sep 1;110(9):551-557
Astuti D, Sabir A, Fulton P, Zatyka M, Williams D, Hardy C, Milan G, Favaretto F, Yu-Wai-Man P, Rohayem J, López de Heredia M, Hershey T, Tranebjaerg L, Chen JH, Chaussenot A, Nunes V, Marshall B, McAfferty S, Tillmann V, Maffei P, Paquis-Flucklinger V, Geberhiwot T, Mlynarski W, Parkinson K, Picard V, Bueno GE, Dias R, Arnold A, Richens C, Paisey R, Urano F, Semple R, Sinnott R, Barrett TG. Monogenic diabetes syndromes: Locus-specific databases for Alström, Wolfram, and Thiamine-responsive megaloblastic anemia. Hum Mutat. 2017 Jul;38(7):764-777
Rätsep T, Asser T. The effect of subthalamic stimulation on viscoelastic stiffness of skeletal muscles in patients with Parkinson's disease. Clin Biomech (Bristol, Avon). 2017 May;44:94-98
Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, Bork P, Wüllner U. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients. Genome Med. 2017 Apr 28;9(1):39. doi: 10.1186/s13073-017-0428-y. Erratum in: Genome Med. 2017 Jun 29;9(1):61
Planken A, Kurvits L, Reimann E, Kadastik-Eerme L, Kingo K, Kõks S, Taba P. Looking beyond the brain to improve the pathogenic understanding of Parkinson's disease: implications of whole transcriptome profiling of Patients' skin. BMC Neurol. 2017 Jan 10;17(1):6
Kingswood JC, d'Augères GB, Belousova E, Ferreira JC, Carter T, Castellana R, Cottin V, Curatolo P, Dahlin M, de Vries PJ, Feucht M, Fladrowski C, Gislimberti G, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Nabbout R, O'Callaghan F, Benedik MP, Qin J, Marques R, Sander V, Sauter M, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen AC; TOSCA consortium and TOSCA investigators.. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. Orphanet J Rare Dis. 2017 Jan 5;12(1):2
Beheshti I, Maikusa N, Matsuda H, Demirel H, Anbarjafari G; Japanese-Alzheimer’s Disease Neuroimaging Initiative.. Histogram-Based Feature Extraction from Individual Gray Matter Similarity-Matrix for Alzheimer's Disease Classification. J Alzheimers Dis. 2017;55(4):1571-1582
Beheshti I, Maikusa N, Daneshmand M, Matsuda H, Demirel H, Anbarjafari G; Japanese-Alzheimer’s Disease Neuroimaging Initiative.. Classification of Alzheimer's Disease and Prediction of Mild Cognitive Impairment Conversion Using Histogram-Based Analysis of Patient-Specific Anatomical Brain Connectivity Networks. J Alzheimers Dis. 2017;60(1):295-304
Asser A., Kõks S., Snellman A., Haaparanta-Solin M., Arponen
E., Grönroos T., Nairismägi J., Bergquist J., Soomets U.,
Piip P., Eltermaa M., Sauk M., Lindmäe H., Rinne JO., Taba
P. Increased striatal VMAT2 binding in mice after chronic
administration of methcathinone and manganese Brain
Research: 1652, 97-102, 2016
Juurmaa J., Menke RA., Vila P., Müürsepp A., Tomberg T.,
Ilves P., Nigul M., Johansen-Berg H., Donaghy M., Stagg CJ.,
Stepens A6, Taba P. Grey matter abnormalities in
methcathinone abusers with a Parkinsonian syndrome Brain and
Behavior: 6 (11), Artikkel nr e00539, 2016
Kadastik-Eerme L., Muldmaa M., Lilles S., Rosenthal M., Taba
N., Taba P. Nonmotor Features in Parkinson's Disease: What
Are the Most Important Associated Factors? Parkinson's
Disease: 2016, Artikkel nr 4370674, 2016
Nõmm S., Toomela A., Vaske M., Uvarov D., Taba P. An
Alternative Approach to Distinguish Movements of Parkinson
Disease Patients IFAC-PapersOnLine: 49 (19), 272-276, 2016
Rätsep T., Asser T. Placebo effects induced by auditory cues
decrease parkinsonian rigidity in patients with subthalamic
stimulation Behavioural Brain Research: 301, 27-32, 2016
Sabre L., Braschinsky M., Taba P. Neurosyphilis as a great
imitator: a case report BMC Research Notes: 9 (1), Artikkel
nr 372, 2016
Toomsoo T., Liepelt-Scarfone I., Kerner R., Kadastik-Eerme
L., Asser T., Rubanovitš I., Berg D., Taba P. Substantia
Nigra Hyperechogenicity: Validation of Transcranial
Sonography for Parkinson Disease Diagnosis in a Large
Estonian Cohort Journal of Ultrasound in Medicine: 35 (1),
17-23, 2016
Asser A., Taba P. Psychostimulants and movement disorders
Frontiers in Neurology: 6, Artikkel nr UNSP 75, 2015
Kadastik-Eerme L., Rosenthal M., Paju T., Muldmaa M., Taba
P. Health-related quality of life in Parkinson's disease: a
cross-sectional study focusing on non-motor symptoms Health
and Quality of Life Outcomes: 13, Artikkel nr 83, 2015
Kunze U., International Scientific Working Group on
Tick-Borne Encephalitis (ISW-TBE) Tick-borne encephalitis as
a notifiable disease - Status quo and the way forward.
Report of the 17th annual meeting of the International
Scientific Working Group on Tick-Borne Encephalitis
(ISW-TBE) Ticks and Tick-borne Diseases: 6 (5), 545-548,
2015
Medijainen K., Pääsuke M., Lukmann A., Taba P. Functional
Performance and Associations between Performance Tests and
Neurological Assessment Differ in Men and Women with
Parkinson's Disease Behavioural Neurology: 2015, Artikkel nr
519801, 2015
Miller DH., Fox RJ., Phillips JT., Hutchinson M., Havrdova
E., Kita M., Wheeler-Kingshott CA., Tozer DJ., MacManus DG.,
Yousry TA., Goodsell M., Yang M., Zhang R., Viglietta V.,
Dawson KT., Comparator and an Oral Fumarate in
Relapsing-Remitting Multiple Sclerosis (CONFIRM) Study
Effects of delayed-release dimethyl fumarate on MRI measures
in the phase 3 CONFIRM study Neurology: 84 (11), 1145-1152,
2015
Antsov E., Silveira-Moriyama L., Kilk S., Kadastik-Eerme L.,
Toomsoo T., Lees AJ., Taba P. Adapting the Sniffin' Sticks
olfactory test to diagnose Parkinson's disease in Estonia
Parkinsonism & Related Disorders: 20 (8), 830-833, 2014
Filippi M., Rocca MA., Pagani E., De Stefano N., Jeffery D.,
Kappos L., Montalban X., Boyko A., Comi G., Assessment of
Oral Laquinimod in Preventing Progression in Multiple
Sclerosis (ALLEGRO) Study Group Placebo-controlled trial of
oral laquinimod in multiple sclerosis: MRI evidence of an
effect on brain tissue damage Journal of Neurology,
Neurosurgery and Psychiatry: 85 (8), 852-859, 2014
Mencacci NE., Isaias IU., Reich MM., Ganos C., Plagnol V.,
Polke JM., Bras J., Hersheson J., Stamelou M., Pittman AM.,
Noyce AJ., Mok KY., Opladen T., Kunstmann E., Hodecker S.,
Münchau A., Volkmann J., Samnick S., Sidle K., Nanji T.,
Sweeney MG., Houlden H., Batla A., Zecchinelli AL., Pezzoli
G., Marotta G., Lees AJ., Alegria P., Krack P.,
Cormier-Dequaire F., Lesage S., Brice A., Heutink P., Gasser
T., Lubbe SJ., Morris HR., Taba P., Kõks S., Majounie E.,
Raphael Gibbs J., Singleton AB., Hardy J., Klebe S., Bhatia
KP., Wood NW., International Parkinson's Disease Genomics
Consortium (IPDGC), University College London Exomes
Consortium (UCL-Exomes Consortium) Parkinson's disease in
GTP cyclohydrolase 1 mutation carriers Brain: 137 (Pt 9),
2480-2492, 2014
Pahwa R., Lyons KE., Hauser RA., Fahn S., Jankovic J.,
Pourcher E., Hsu A., O'Connell M., Kell S., Gupta S.,
APEX-PD Investigators Randomized trial of IPX066,
carbidopa/levodopa extended release, in early Parkinson's
disease Parkinsonism & Related Disorders: 20 (2), 142-148,
2014
Raudmann M., Taba P., Medijainen K. Handwriting speed and
size in individuals with Parkinson’s disease compared to
healthy controls: the possible effect of cueing Acta
Kinesiologiae Universitatis Tartuensis: 20, 40-47, 2014
Rätsep T., Abel A., Linnamägi Ü. Patient involvement in
surgical treatment decisions and satisfaction with the
treatment results after lumbar intervertebral discectomy
European Spine Journal: 23 (4), 873-881, 2014
Berardelli A., Wenning GK., Antonini A., Berg D., Bloem BR.,
Bonifati V., Brooks D., Burn DJ., Colosimo C., Fanciulli A.,
Ferreira J., Gasser T., Grandas F., Kanovsky P., Kostic V.,
Kulisevsky J., Oertel W., Poewe W., Reese JP., Relja M.,
Ruzicka E., Schrag A., Seppi K., Taba P., Vidailhet M.
EFNS/MDS-ES recommendations for the diagnosis of Parkinson's
disease European Journal of Neurology: 20 (1), 16-34, 2013
Kunze U., International Scientific Working Group on
Tick-Borne Encephalitis (ISW-TBE) Tick-borne encephalitis -
a notifiable disease Report of the 15th Annual Meeting of
the International Scientific Working Group on Tick-Borne
Encephalitis (ISW-TBE) Ticks and Tick-borne Diseases: 4 (5),
363-365, 2013
Lill M., Kõks S., Soomets U., Schalkwyk LC., Fernandes C.,
Lutsar I., Taba P. Peripheral blood RNA gene expression
profiling in patients with bacterial meningitis Frontiers in
Neuroscience: 7, Artikli nr 33, 2013
Lubi K., Vihalemm T., Krikmann Ü., Paju T., Taba P. “There
is no need to tell me too much”: chronically ill
patients’strategies of controlling information inflow
International Journal of Communication and Health: 1, 24-30,
2013
Rätsep T., Minajeva A., Asser T. Relationship between
neovascularization and degenerative changes in herniated
lumbar intervertebral discs European Spine Journal: 22 (11),
2474-2480, 2013
Sikk K., Haldre S., Aquilonius SM., Asser A., Paris M.,
Roose Ä., Petterson J., Eriksson SL., Bergquist J., Taba P.
Manganese-induced parkinsonism in methcathinone abusers:
bio-markers of exposure and follow-up European Journal of
Neurology: 20 (6), 915-920, 2013
Taba P. Metals and movement disorders Current Opinion in
Neurology: 26 (4), 435-441, 2013
Taba P., Lees AJ., Stern G. Erich Harnack (1852-1915) and a
short history of apomorphine European Neurology: 69 (6),
321-324, 2013
Vetkas A., Lepik T., Eilat T., Rätsep T., Asser T. Emotional
health and quality of life after aneurysmal subarachnoid
hemorrhage Acta Neurochirurgica: 155 (6), 1107-1114, 2013
Comi G., Jeffery D., Kappos L., Montalban X., Boyko A.,
Rocca MA., Filippi M., Assessment of Oral Laquinimod in
Preventing Progression in Multiple Sclerosis (ALLEGRO) Study
Group Placebo-controlled trial of oral laquinimod for
multiple sclerosis New England Journal of Medicine: 366
(11), 1000-1009, 2012
Fox RJ., Miller DH., Phillips JT., Hutchinson M., Havrdova
E., Kita M., Yang M., Raghupathi K., Novas M., Sweetser MT.,
Viglietta V., Dawson KT., Comparator and an Oral Fumarate in
Relapsing-Remitting Multiple Sclerosis (CONFIRM) Study
Investigators. Placebo-Controlled Phase 3 Study of Oral
BG-12 or Glatiramer in Multiple Sclerosis New England
Journal of Medicine: 367 (12), 1087-1097, 2012
Kunze U., International Scientific Working Group on
Tick-Borne Encephalitis (ISW-TBE) Tick-borne encephalitis
(TBE): an underestimated riskstill: report of the 14th
annual meeting of the International Scientific Working Group
on Tick-Borne Encephalitis (ISW-TBE) Ticks and Tick-borne
Diseases: 3 (3), 197-201, 2012
Liik M., Puksa L., Lüüs SM., Haldre S., Taba P. Fulminant
inflammatory neuropathy mimicking cerebral death BMJ Case
Reports: 2012, 2012
Rätsep T. Postoperative spondylodiscitis caused by
Mycobacterium bovis BCG: a case study Spine Journal: 12
(12), E1-E5, 2012
Rätsep T., Asser T. Subthalamic stimulation improves the
cerebral hemodynamic response to the cold pressure test in
patients with Parkinson's disease Journal of Clinical
Ultrasound: 40 (9), 547-553, 2012
Taba P., Rosenthal M., Habicht J., Tarien H., Mathiesen M.,
Hill SR., Bero LA. Barriers and facilitators to the
implementation of clinical practice guidelines: A
cross-sectional survey among physicians in Estonia BMC
Health Services Research: 12, 455, 2012
Comi G., Cohen JA., Arnold DL., Wynn D., Filippi M., Forty
mg efficacy of glatiramer acetate (FORTE) study group Phase
III Dose-Comparison Study of Glatiramer Acetate for Multiple
Sclerosis Annals of Neurology: 69 (1), 75-82, 2011
Ling H., Braschinsky M., Taba P., Lüüs SM., Doherty K.,
Hotter A., Poewe W., Lees AJ. Decades of delayed diagnosis
in 4 levodopa-responsive young-onset monogenetic
parkinsonism patients Movement Disorders: 26 (7), 1337-1340,
2011
Rätsep T., Asser T. Changes in viscoelastic properties of
skeletal muscles induced by subthalamic stimulation in
patients with Parkinson's disease Clinical Biomechanics: 26
(2), 213-217, 2011
Sikk K., Haldre S., Aquilonius SM., Taba P.
Manganese-Induced Parkinsonism due to Ephedrone Abuse
Parkinson's Disease: 2011 (1), 2011
Sikk K., Kõks S., Soomets U., Schalkwyk LC., Fernandes C.,
Haldre S., Aquilonius SM., Taba P. Peripheral blood RNA
expression profiling in illicit methcathinone users reveals
effect on immune system Frontiers in Genetics: 2, 42, 2011
A'Campo LEI., Spliethoff-Kamminga NGA., Macht M., Roos RAC.,
Patient education in parkinson's disease (EduPark) Caregiver
education in Parkinson's disease: formative evaluation of a
standardized program in seven European countries Quality of
Life Research: 19 (1), 55-64, 2010
Giovannoni G., Comi G., Cook S., Rammohan K., Rieckmann P.,
Sorensen PS., Vermersch P., Chang P., Hamlett A., Musch B.,
Greenberg SJ., Cladribine Tablets Treating Multiple
Sclerosis Orally (CLARITY) Study Group A Placebo-Controlled
Trial of Oral Cladribine for Relapsing Multiple Sclerosis
New England Journal of Medicine: 362 (5), 416-426, 2010
Sikk K., Taba P., Haldre S., Bergquist J., Nyholm D.,
Askmark H., Danfors T., Sörensen J., Thurfjell L., Raininko
R., Eriksson R., Flink R., Färnstrand C., Aquilonius SM.
Clinical, neuroimaging and neurophysiological features in
addicts with manganese-ephedrone exposure Acta Neurologica
Scandinavica: 121 (4), 237-243, 2010
Krikmann Ü., Taba P., Lai T., Asser T. Validation of an
Estonian version of the Parkinson's Disease Questionnaire
(PDQ-39) Health and Quality of Life Outcomes: 6, Artikli nr
23, 2008
Lewis SC., Warlow CP., Bodenham AR., Colam B., Rothwell PM.,
Torgerson D., Dellagrammaticas D., Horrocks M., Liapis C.,
Banning AP., Gough M., Gough MJ., General anaesthesia versus
local anaesthesia for carotid surgery (GALA) trial
collaborative group General anaesthesia versus local
anaesthesia for carotid surgery (GALA): a multicentre,
randomised controlled trial The Lancet: 372 (9656), 2132 -
2142, 2008
Macht M., Gerlich C., Ellgring H., Schradi M., Rusinol AB.,
Crespo M., Prats A., Viemero V., Lankinen A., Bitti PER.,
Candini L., Spliethoff-Kamminga NGA., de Vreugd J., Simons
G., Pasqualini MS., Thompson SBN., Taba P., Krikmann Ü.,
Kanarik E. Patient education in Parkinson's disease:
Formative evaluation of a standardized programme in seven
European countries Patient Education and Counseling: 65 (2),
245-252, 2007
Macht M., Pasqualini MS., Taba P. Cognitive-behavioral
strategies for Parkinson's disease: A report of three cases
Journal of Clinical Psychology in Medical Settings: 14 (2),
165-176, 2007
Sikk K., Taba P., Haldre S., Bergquist J., Nyholm D.,
Zjablov G., Asser T., Aquilonius SM. Irreversible motor
impairment in young addicts - ephedrone, manganism or both?
Acta Neurologica Scandinavica: 115 (6), 385-389, 2007
Publikatsioonid ajakirjas „Eesti Arst“
Ambos A., Raie E., Kiudma T., Reppo I., Rätsep A.,
Tammiksaar K., Toomsoo T., Volke V. 2. tüüpi diabeedi Eesti
ravijuhend 2016 Eesti Arst: 95 (7), 465-473, 2016
Rallmann K., Liik M., Taba P. Botulismitoksiini kliiniline
kasutamine Eesti Arst: 95 (3), 171-178, 2016
Taba P. Muusika müstika: kas emotsionaalne nauding või
ravimeetod? Eesti Arst: 95 (11), 749-749, 2016
Hunt H., Säälik P., Toome K., Vetkas A., Asser A., Rätsep
T., Asser T., Teesalu T. Hõbekuulid vähiteraapias: teel
suunatud vähiravi poole Eesti Arst: 94 (5), 281-287, 2015
Toomsoo T., Asser T., Taba P. Transkraniaalne
ultraheliuuring Parkinsoni tõve diagnoosimisel Eesti Arst:
94 (Lisa 4), 100-105, 2015
Lubi K., Vihalemm T., Taba P. Patsiendid infootsijana:
väljakutsed, võimalused ja ohud Parkinsoni tõvega
patsientide näitel Eesti Arst: 93 (2), 76-82, 2014
Sikk K., Haldre S., Aquilonius SM., Taba P. Toksiline
parkinsonism psühhostimulanti süstivatel noortel
narkomaanidel Eesti Arst: 92 (6), 320-324, 2013
Vetkas A., Mehevits K., Rätsep T., Asser T. Spontaanse
subarahnoidaalse hemorraagia diagnoosimise kiirus ja seda
mõjutavad tegurid Eesti Arst: 90 (8), 366-371, 2011
Kõrv J., Gross-Paju K., Haldre S., Jaakmees H., Kreis A.,
Kullamaa S., Liigant A., Lüüs SM., Taba P., Õunapuu A.
Insuldi käsitlus Eestis: hetkeseis ja suundumused Eesti
Arst: 89 (6), 409-415, 2010
Krikmann Ü., Kalbe I., Lüüs SM., Taba P., Õunapuu A.
Neuroborrelioos - puukidega leviv närvisüsteemi bakternakkus
Eesti Arst: 87 (3), 214-220, 2008
Toomsoo T., Taba P. Treemorid Eesti Arst: 87 (6), 424-430,
2008
Braschinsky M., Vibo R., Rallmann K., Asser A., Tomberg T.
Aju venoossete siinuste tromboos Eesti Arst: 86 (12),
897-902, 2007
Krikmann Ü., Kalbe I., Lüüs SM., Taba P., Õunapuu A.
Puukentsefaliit – sage närvisüsteeemi viirushaigus Eesti
Arst: 86 (4), 273-276, 2007
Lill M., Seeman S., Taba P., Lüüs SM. Locked-in sündroom
Eesti Arst: 85 (6), 387-393, 2006
Raamatud, peatükid raamatutes:
Lubi K., Vihalemm T., Taba P. Patients’ interpretations of
CAM-related information: manoeuvring between patient and
consumer positionings The Power of the Media in Health
Communication: 71-90, 2016
Stepens A., Taba P. The Neuropathology of Movement Disorders
in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) and
Methcathinone (Ephedrone) Addictions Neuropathology of Drug
Addictions and Substance Misuse: 3, 924–934, 2016
Jürisson M., Taba P., Võrno T., Abram M., Eiche IE., Uusküla
A. Puukentsefaliidivastase vaktsineerimise kulutõhusus
Eestis Puukentsefaliidivastase vaktsineerimise kulutõhusus
Eestis: 111, 2015
Lees AJ., Sikk K., Taba P. The Story of "Speed" from "Cloud
Nine" to Brain Gain International Review of Neurobiology:
120, 1-7, 2015
Sikk K., Taba P. Methcathinone “Kitchen Chemistry” and
Permanent Neurological Damage International Review of
Neurobiology: 120, 257-271, 2015
Taba P., Lees AJ., Sikk K. The Neuropsychiatric
Complications of Stimulant Abuse The Neuropsychiatric
Complications of Stimulant Abuse: 388, 2015
Taba P., Lutsar I. Chronic Infectious Inflammatory Diseases
of the Central Nervous System Cerebrospinal Fluid in
Clinical Neurology: 211-245, 2015
Lubi K., Vihalemm T., Taba P. Illness-related Information
Seeking: The Case of Parkinson's Disease Patients Advances
in Education Research. 2014 2nd International Conference on
Social Science and Health (ICSSH 2014): 59, 98-111, 2014
Taba P. Movement disorders associated with chronic metal
poisoning Movement Disorders in Neurologic and Systemic
Disease: 220-233, 2014
Sikk K. Manganese-ephedrone intoxication – pathogenesis of
neurological damage and clinical symptomatology
Dissertationes medicinae Universitatis Tartuensis: 206, 125,
2013
Taba P. Parkinsoni tõve ravi Eakate farmakoteraapia:
307-318, 2012
Taba P., Krikmann Ü., Kanarik E. Introduccion. Informacion
Psicoeducation para afectados de Parkinson y sus cuidadores:
23-43, 2007
Uueni D., Pääsuke M., Gapeyeva H., Ereline J., Kums T.,
Noorvee K., Taba P. Motoorse võimekuse näitajad mõõdukalt
väljendunud Parkinsoni tõvega patsientidel ja kontrollgrupil
Kehakultuuriteaduskonna teadus- ja õppemetoodiliste tööde
kogumik: 85-94, 2007
Macht M., Ellgring H., Gerlich C., Haapaniemi H., Krikmann
Ü., Leino P., Routasalo P., Taba P. Informationsbedürfnisse
bei Parkinson-Patienten in Estland, Finnland und Deutschland
Beschreiben – Erschließen – Erläutern:
Psychotherapieforschung als qualitative Wissenschaft:
340-353, 2006
Taba P., Krikmann Ü., Kanarik E. Einfürhung in das Programm
und Informationssuche Psychosoziales Training bei
neurologischen Erkrankungen - Schwerpunkt Parkinson. Ein
Programm für die Schulung von Patienten und Angehörigen:
39-51, 2006
Taba P., Krikmann Ü., Kanarik E. Information Patient
education for people with Parkinson's disease and their
carers : a manual / edited by Marcia Smith Pasqualini and
Gwenda Simons: 27-46, 2006
Taba P., Krikmann Ü., Kanarik E. Introduzione Intervento
psicoeducativo nella malattia di Parkinson : il programma
EduPark/ Pio Enrico Ricci Bitti ... [et al.]: 45-65, 2006
Sikk K. Manganese-ephedrone intoxication – pathogenesis of
neurological damage and clinical symptomatology
Dissertationes medicinae Universitatis Tartuensis: 206, 125,
2013
Taba P. Parkinsoni tõve ravi Eakate farmakoteraapia:
307-318, 2012
Taba P., Krikmann Ü., Kanarik E. Introduccion. Informacion
Psicoeducation para afectados de Parkinson y sus cuidadores:
23-43, 2007
Uueni D., Pääsuke M., Gapeyeva H., Ereline J., Kums T.,
Noorvee K., Taba P. Motoorse võimekuse näitajad mõõdukalt
väljendunud Parkinsoni tõvega patsientidel ja kontrollgrupil
Kehakultuuriteaduskonna teadus- ja õppemetoodiliste tööde
kogumik: 85-94, 2007
Macht M., Ellgring H., Gerlich C., Haapaniemi H., Krikmann
Ü., Leino P., Routasalo P., Taba P. Informationsbedürfnisse
bei Parkinson-Patienten in Estland, Finnland und Deutschland
Beschreiben – Erschließen – Erläutern:
Psychotherapieforschung als qualitative Wissenschaft:
340-353, 2006
Taba P., Krikmann Ü., Kanarik E. Einfürhung in das Programm
und Informationssuche Psychosoziales Training bei
neurologischen Erkrankungen - Schwerpunkt Parkinson. Ein
Programm für die Schulung von Patienten und Angehörigen:
39-51, 2006
Taba P., Krikmann Ü., Kanarik E. Information Patient
education for people with Parkinson's disease and their
carers : a manual / edited by Marcia Smith Pasqualini and
Gwenda Simons: 27-46, 2006
Taba P., Krikmann Ü., Kanarik E. Introduzione Intervento
psicoeducativo nella malattia di Parkinson : il programma
EduPark/ Pio Enrico Ricci Bitti ... [et al.]: 45-65, 2006
Muud publikatsioonid
Taba P. Treemorid Perearst: 6 (104), 44-47, 2015
Taba P., Asser T., Krikmann Ü., Paju T., Olt E., Kanarik E.,
Ankru K., Kivil H., Taurafeldt E., Aasa M. Болезнь
Паркинсона : книга для больных и их семей. III Болезнь
Паркинсона : книга для больных и их семей. III: 106 lk, 2012
Taba P. Ludvig Puusepa nim Neuroloogide ja Neurokirurgide
Selts 2009. aastal Lege Artis: 6(96), 37-37, 2010
Taba P. Parkinsoni tõve ravi - probleemid ja lahendused Lege
Artis: 5(95), 11-16, 2010
Taba P., Asser T., Krikmann Ü., Paju T., Olt E., Kanarik E.,
Ankru K., Kivil H., Taurafeldt E., Aasa M. Parkinsoni tõve
Eesti ravijuhend Parkinsoni tõve Eesti ravijuhend: 102, 2008
Toomsoo T. Naised ja migreen - kas insuldi risk on suurem?
Lege Artis: Lisa (juuni), 35-38, 2008
Taba P., Asser T., Krikmann Ü., Paju T., Olt E., Kanarik E.,
Ankru K., Kivil H., Taurafeldt E., Aasa M. Parkinsoni tõbi:
raamat haigetele ja nende peredele III Parkinsoni tõbi:
raamat haigetele ja nende peredele III: 104, 2007
Toomsoo T. Rasagiliin teeb soovitud tulemuse lihtsaks
Hippokrates: 9 (80), 354-356, 2007